344 related articles for article (PubMed ID: 11456380)
1. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
Han SH; De Klerk JM; Zonnenberg BA; Tan S; Van Rijk PP
Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
[TBL] [Abstract][Full Text] [Related]
2. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
Piffanelli A; Dafermou A; Giganti M; Colamussi P; Pizzocaro C; Bestagno M;
Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368
[TBL] [Abstract][Full Text] [Related]
3. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
Han SH; de Klerk JM; Tan S; van het Schip AD; Derksen BH; van Dijk A; Kruitwagen CL; Blijham GH; van Rijk PP; Zonnenberg BA
J Nucl Med; 2002 Sep; 43(9):1150-6. PubMed ID: 12215552
[TBL] [Abstract][Full Text] [Related]
4. 186Re-etidronate in breast cancer patients with metastatic bone pain.
Han SH; Zonneberg BA; de Klerk JM; Quirijnen JM; van het Schip AD; van Dijk A; Blijham GH; van Rijk PP
J Nucl Med; 1999 Apr; 40(4):639-42. PubMed ID: 10210223
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
[TBL] [Abstract][Full Text] [Related]
6. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
[TBL] [Abstract][Full Text] [Related]
7. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
[TBL] [Abstract][Full Text] [Related]
8. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ
J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
[TBL] [Abstract][Full Text] [Related]
9. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
10. 186Re-HEDP for metastatic bone pain in breast cancer patients.
Lam MG; de Klerk JM; van Rijk PP
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
[TBL] [Abstract][Full Text] [Related]
11. [Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
Klutmann S; Bohuslavizki KH
MMW Fortschr Med; 1999 Nov; 141(44):38-9. PubMed ID: 10912142
[TBL] [Abstract][Full Text] [Related]
12. Systemic radionuclide therapy in pain palliation.
Liepe K; Runge R; Kotzerke J
Am J Hosp Palliat Care; 2005; 22(6):457-64. PubMed ID: 16323716
[TBL] [Abstract][Full Text] [Related]
13. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.
Sciuto R; Festa A; Pasqualoni R; Semprebene A; Rea S; Bergomi S; Maini CL
Breast Cancer Res Treat; 2001 Mar; 66(2):101-9. PubMed ID: 11437096
[TBL] [Abstract][Full Text] [Related]
14. Application of rhenium-188 HEDP in bone metastases therapy.
Scheffler J; Derejko M; Bandurski T; Romanowicz G
Nucl Med Rev Cent East Eur; 2003; 6(1):55-7. PubMed ID: 14600935
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain.
Quirijnen JM; Han SH; Zonnenberg BA; de Klerk JM; van het Schip AD; van Dijk A; ten Kroode HF; Blijham GH; van Rijk PP
J Nucl Med; 1996 Sep; 37(9):1511-5. PubMed ID: 8790203
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
17. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
Zafeirakis A; Zissimopoulos A; Baziotis N; Limouris GS
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):91-102. PubMed ID: 21068716
[TBL] [Abstract][Full Text] [Related]
18. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
de Klerk JM; Zonnenberg BA; Krouwer HG; Blijham GH; van Dijk A; van het Schip AD; van Die J; van Rijk PP
J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
[TBL] [Abstract][Full Text] [Related]
19. Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer.
Leondi AH; Souvatzoglou MA; Rapti AS; Leontopoulou SA; Papadaki EK; Datseris EI; Anagnostopoulou US; Zerva CJ
Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):211-9. PubMed ID: 15499295
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
de Klerk JM; van Dijk A; van het Schip AD; Zonnenberg BA; van Rijk PP
J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
